Upcoming Events
Mar 28, 2023 at 9:15 AM EDT
Biogen at the Stifel 2023 CNS Days
Past Events
Mar 6, 2023 at 9:50 AM EST
Biogen at the 43rd Annual TD Cowen Health Care Conference
Feb 15, 2023 at 8:00 AM EST
Q4 and Full Year 2022 Earnings Call Webcast
Jan 9, 2023 at 2:15 PM EST
Biogen at the 41st Annual J.P. Morgan Healthcare Conference
Dec 6, 2022 at 8:00 AM EST
Biogen and Sage Zuranolone Webcast
Dec 1, 2022 at 10:30 AM EST
5th Annual Evercore ISI HealthCONx Conference
Nov 29, 2022 at 7:50 PM EST
Clarity AD: Lecanemab Phase 3 Data Presentation Webcast at CTAD
Oct 25, 2022 at 8:00 AM EDT
Q3 2022 Earnings Call Webcast
Sep 12, 2022 at 9:55 AM EDT
Biogen at the Morgan Stanley 20th Annual Global Healthcare Conference
Jul 20, 2022 at 8:00 AM EDT
Q2 2022 Earnings Call Webcast
Jun 15, 2022 at 9:00 AM EDT
2022 Annual Meeting of Stockholders
May 3, 2022 at 8:00 AM EDT
Q1 2022 Earnings Call Webcast
Mar 28, 2022 at 10:15 AM EDT
Biogen at the Stifel 2022 CNS Days
Mar 7, 2022 at 9:50 AM EST
Biogen at the Cowen 42nd Annual Health Care Conference
Nov 11, 2021 at 5:10 PM EST
Dose and time dependent changes in plasma ptau181 in patients treated with aducanumab in the ENGAGE and EMERGE trials at CTAD
View Presentation 778.4 KB
Nov 9, 2021 at 8:00 AM EST
Baseline EMBARK data from EMERGE, ENGAGE, and PRIME participants in the EMBARK re-dosing study at CTAD
View Presentation 425 KB
Oct 17, 2021 at 4:20 PM EDT
Results from the Phase 3 VALOR study and its open-label extension at ANA 2021
View Presentation 934.2 KB
Sep 21, 2021 at 10:00 AM EDT
Biogen Investor R&D Day
Jun 8, 2021 at 8:00 AM EDT
Biogen ADUHELM Launch Webcast
Biogen ADUHELM Launch 4.3 MB
Mar 13, 2021
Evaluation of aducanumab efficacy in early Alzheimer’s disease at AD/PD
View Presentation 793.4 KB
Mar 13, 2021
Evaluation of aducanumab efficacy and safety in early Alzheimer’s disease Discussion at AD/PD
Mar 13, 2021
Evaluation of aducanumab safety in early Alzheimer’s disease at AD/PD
View Presentation 305.7 KB
Mar 10, 2021
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD
View Presentation 480.1 KB
Mar 10, 2021
Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE Discussion at AD/PD
Feb 23, 2021
Aducanumab data review and Q&A with Global Alzheimer's Platform
View Presentation 2.4 MB
Jan 14, 2021 at 9:00 AM EST
Aducanumab data review and Q&A with Alzheimer's Disease International
View Presentation 2.2 MB
Nov 30, 2020 at 9:00 AM EST
Biogen and Sage Collaboration Webcast
Nov 4, 2020 at 10:15 AM EST
Aducanumab EMBARK study design and Q&A at CTAD 2020
View Presentation 751.9 KB
Sep 23, 2020
Aducanumab Phase 3 Topline Results at the AAN 2020 Science Highlights (encore virtual presentation replay)
Sep 19, 2020
Aducanumab Phase 3 Topline Results at the 23rd Chinese National Conference of Neurology (encore virtual presentation replay)
View Presentation 795 KB
Aug 31, 2020
Biogen at the 61st Annual Meeting of the Japanese Society of Neurology (replay)
View Presentation 1.5 MB
Jul 29, 2020 at 7:00 AM CDT
Aducanumab Phase 3 Topline Results at AAIC (encore presentation and Q&A replay)
View Presentation 512.4 KB
Jun 23, 2020 at 12:30 PM EDT
Biogen to Participate in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum (replay)
May 18, 2020
Aducanumab Phase 3 Topline Results at AAN (encore virtual presentation replay)
View Presentation 775.1 KB
May 11, 2020
Biogen at the 2020 World Medical Innovation Forum (replay)
Apr 2, 2020 at 6:00 PM EDT
Aducanumab Phase 3 Topline Results at AAT-AD/PD (encore presentation replay)
View Presentation 1.1 MB
Dec 5, 2019 at 5:00 PM EST
Investor Q&A call following CTAD Presentation (replay)
Dec 5, 2019 at 11:00 AM EST
Aducanumab Phase 3 Topline Results at CTAD (replay)
View Presentation 1.6 MB
Jun 5, 2019 at 8:00 AM EDT
Biogen Webcast on ALS Portfolio (replay)